BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10901441)

  • 1. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
    Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
    J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells.
    Morgan K; Stavrou E; Leighton SP; Miller N; Sellar R; Millar RP
    Prostate; 2011 Jun; 71(9):915-28. PubMed ID: 21541969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
    Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone.
    Enomoto M; Seong JY; Kawashima S; Park MK
    Life Sci; 2004 May; 74(25):3141-52. PubMed ID: 15081579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
    Zhao LJ; Liu N; Li XP; Wang JL; Wei LH
    Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate.
    Janssen T; Darro F; Petein M; Raviv G; Pasteels JL; Kiss R; Schulman CC
    Cancer; 1996 Jan; 77(1):144-9. PubMed ID: 8630922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
    Günthert AR; Gründker C; Hollmann K; Emons G
    Biochem Biophys Res Commun; 2002 May; 294(1):11-5. PubMed ID: 12054733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
    Kakar SS
    Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
    Lee G; Ge B
    Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines.
    Kampa M; Hatzoglou A; Notas G; Damianaki A; Bakogeorgou E; Gemetzi C; Kouroumalis E; Martin PM; Castanas E
    Nutr Cancer; 2000; 37(2):223-33. PubMed ID: 11142097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
    Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
    Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.